Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.
EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19 with ImmunoPrecise, the benefits of a computational approach to antibody research and drug discovery, our progress as a company and a host of other topics.
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV’s optimism on the project.
Brett Averso (CTO, EVQLV) shows and explains the undeniable structural similarities between SARS-CoV-2 and SARS. We hope this video serves to dispel some of the myths you may have encountered during your search for answers surrounding coronavirus.
The SARS antibodies are not cross-reactive with SARS-Cov-2. However, we can potentially use artificial intelligence to design variants of the existing SARS antibodies which are cross-reactive with SARS-CoV-2.
Brett Averso, CTO, and I recently had a follow up discussion on our first coronavirus chat. Brett provided visualizations and commentary on coronavirus (SARS-CoV-2), ACE2, SARS-CoV-2 with SARS overlay, and antibody fragments to help people better understand the threat we’re currently facing, as well as put it in its proper context. Brett also discussed the role AI can play in finding an effective treatment for COVID-19.
Columbia Data Science Institute recently covered EVQLV’s work towards developing therapeutic candidates against COVID-19 with Immunoprecise Antibodies.